Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats.
J Cardiovasc Pharmacol
; 83(6): 621-634, 2024 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-38547520
ABSTRACT
ABSTRACT Type 2 diabetes mellitus increases the risk of cardiovascular diseases. Therefore, elucidation of the cardiovascular effects of antidiabetics is crucial. Incretin-based therapies are increasingly used for type 2 diabetes mellitus treatment as monotherapy and in combination. We aimed to study the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sitagliptin on beating rates in isolated atria from diabetic rats. The chronotropic responses to GLP-1 RAs and sitagliptin as monotherapy and in combinations with metformin, pioglitazone, and glimepiride in isolated atria from control and diabetic rats were determined. GLP-1 (7-36), GLP-1 (9-36), and exendin-4 (1-39) produced increases in beating rates in both control and diabetic rat atria. However, sitagliptin increased the beating frequency only in the diabetic group. Exendin (9-39), nitro- l -arginine methyl ester hydrochloride, and indomethacin blocked responses to GLP-1 RAs but not the response to sitagliptin. Glibenclamide, 4-aminopyridine, apamin, charybdotoxin, superoxide dismutase, and catalase incubations did not change responses to GLP-1 RAs and sitagliptin. GLP-1 RAs increase beating rates in isolated rat atrium through GLP-1 receptor, nitric oxide, and cyclooxygenase pathways but not potassium channels and reactive oxygen radicals.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Experimental
/
Fosfato de Sitagliptina
/
Receptor do Peptídeo Semelhante ao Glucagon 1
/
Átrios do Coração
/
Frequência Cardíaca
/
Hipoglicemiantes
Limite:
Animals
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article